| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:39 UTC |
|---|
| HMDB ID | HMDB0014529 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Valrubicin |
|---|
| Description | Valrubicin is only found in individuals that have used or taken this drug. It is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia ]Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II. |
|---|
| Structure | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C2=C(C1)C(O)=C1C(=O)C3=C(C(=O)C1=C2O)C(OC)=CC=C3 InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14?,17?,19-,22?,27?,33-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Valstar | Kegg | | Antibiotic ad 32 | HMDB | | N-Trifluoroacetyladriamycin 14-valerate | HMDB | | AD-32 | HMDB | | Paladin brand OF valrubicin | HMDB | | Valtaxin | HMDB | | AD 32 | HMDB | | 2,2,2-Trifluoro-N-(3-hydroxy-2-methyl-6-{[(1S,3S)-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-3-[2-(pentanoyloxy)acetyl]-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)ethanimidate | HMDB |
|
|---|
| Chemical Formula | C34H36F3NO13 |
|---|
| Average Molecular Weight | 723.6437 |
|---|
| Monoisotopic Molecular Weight | 723.213874858 |
|---|
| IUPAC Name | 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-{[5-hydroxy-6-methyl-4-(trifluoroacetamido)oxan-2-yl]oxy}-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate |
|---|
| Traditional Name | valrubicin |
|---|
| CAS Registry Number | 56124-62-0 |
|---|
| SMILES | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C2=C(C1)C(O)=C1C(=O)C3=C(C(=O)C1=C2O)C(OC)=CC=C3 |
|---|
| InChI Identifier | InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14?,17?,19-,22?,27?,33-/m0/s1 |
|---|
| InChI Key | ZOCKGBMQLCSHFP-ZQUOIQDWSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Anthracyclines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Anthracyclines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Anthracycline
- Anthracyclinone-skeleton
- Tetracenequinone
- 9,10-anthraquinone
- 1,4-anthraquinone
- Anthracene
- Glycosyl compound
- O-glycosyl compound
- Tetralin
- Aryl ketone
- Anisole
- Alpha-acyloxy ketone
- Fatty acid ester
- Alkyl aryl ether
- Benzenoid
- Fatty acyl
- Monosaccharide
- Oxane
- Vinylogous acid
- Tertiary alcohol
- Alpha-hydroxy ketone
- Carboxamide group
- Carboxylic acid ester
- Secondary alcohol
- Secondary carboxylic acid amide
- Ketone
- Oxacycle
- Organoheterocyclic compound
- Polyol
- Carboxylic acid derivative
- Ether
- Acetal
- Monocarboxylic acid or derivatives
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organofluoride
- Alkyl fluoride
- Organohalogen compound
- Alkyl halide
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 116 - 117 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.032 g/L | Not Available | | LogP | 2.2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.28 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.0395 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.93 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3874.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 170.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 236.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 159.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 155.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 745.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 868.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 110.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1384.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 624.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1950.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 476.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 536.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 198.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 163.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 12.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (Non-derivatized) - 70eV, Positive | splash10-052r-9721263000-df206296c65be0a6cbb1 | 2017-11-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_5) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_1_6) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_7) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_8) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_9) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_10) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_11) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_12) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_13) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_14) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TMS_2_15) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valrubicin GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 10V, Positive-QTOF | splash10-006t-9002402500-9e90dc5748fa5422239d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 20V, Positive-QTOF | splash10-000b-8227901100-a76d64d39b73899671a7 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 40V, Positive-QTOF | splash10-0002-9001100000-d7784aa32a024191964b | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 10V, Negative-QTOF | splash10-0ul0-8900213600-4a94b36c9ac08d2235e2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 20V, Negative-QTOF | splash10-0udi-6913111100-ab3c6472a1ac3db4d29d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 40V, Negative-QTOF | splash10-0udi-5900300000-86e9d02455d0203aaac3 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 10V, Positive-QTOF | splash10-0059-0075902300-624df39e91c9d410f340 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 20V, Positive-QTOF | splash10-004i-2193204100-ba55844b0b476519af81 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 40V, Positive-QTOF | splash10-01r2-1930000000-d31c90e59f9f10e6040c | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 10V, Negative-QTOF | splash10-00dj-8200701900-4541a3e4bf0ecf30a9d7 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 20V, Negative-QTOF | splash10-0204-4405902500-50fd3b26dea6e4d410dc | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valrubicin 40V, Negative-QTOF | splash10-066r-9000000000-65d1acb50c8427e363af | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|